Calls
1
Richard Francis
CEO, Teva Pharmaceutical
Win Rate
0.0%
return
-0.3%
Loading charts...
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jul 29
$34.50
-0.3%
Teva delivered a strong Q2, raised guidance across all metrics, and sees upside in its key products. There is a large unmet patient need that will drive volume growth even as Medicare pricing rules impact pricing. The pipeline includes a Tourette's syndrome treatment with an expected approval around end of Q2 next year, and the company is well-positioned to maximize these opportunities.
Pharma & Biotech
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Richard Francis has 1 trade ideas tracked on Buzzberg across 1 tickers since July 2026. Most covered: TEVA.
